ESLA Stock Forecast: Estrella Immunopharma, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.33
−2.53% on the day

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 26 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$14.6M
Ticker Nerd rank
26/ 100
Median analyst target
$12
Analysts covering
—
Revenue$0.0
Operating income−$2.1M
Net income−$2.3M
Free cash flow−$1.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−35.4%
1M
−17.1%
YTD
−78.7%
1Y
−79.5%
From 52W high
−84.3%
From 52W low
+5.7%
$0.31
$2.12
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Estrella Immunopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
26/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
83
Value
46
Momentum
38
Revisions
29
Growth
29
Issuance
26
Volatility
15
Quality
12

Accruals (83): Reported profit is backed by cash, and the company is not expanding recklessly.

Quality (12): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ESLA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ESLA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00Jan 26Apr 26Jul 26Oct 26ESLAHigh $12Median $12Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first
DateFirmActionRatingTarget
9 Feb 2026D. Boral CapitalMaintainsBuy$8.00
28 Jan 2026D. Boral CapitalMaintainsBuy—
3 Nov 2025D. Boral CapitalMaintainsBuy—
12 Aug 2025D. Boral CapitalMaintainsBuy—
3 June 2025D. Boral CapitalMaintainsBuy—
29 May 2025D. Boral CapitalMaintainsBuy—
21 Feb 2025D. Boral CapitalMaintainsBuy—
18 Feb 2025D. Boral CapitalInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ESLA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ESLA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Estrella Immunopharma, Inc. returned −79.5% against +6.9% for the S&P 500, dividends included.

ESLA vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120140Jan 26Apr 26Jul 26Oct 26ESLAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ESLA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
—
EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
—
Return on assets
−251.9%

Higher than 1% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Estrella Immunopharma, Inc. has a market value of $14.6M and an enterprise value of $16.4M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$10.0M.

  • Free cash flow in the twelve months to 30 June 2026: −$9.4M.

  • Estrella Immunopharma, Inc. spent $0.0 on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 43.0M.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

ESLA and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ESLAEstrella Immunopharma, Inc.$14.6M26
PLURPluri, Inc.$13.5M17
ABOSAcumen Pharmaceuticals, Inc.$13.5M42
NCELNewCelX Ltd.$13.6M4
ACTUActuate Therapeutics, Inc.$13.6M39
BYSIBeyondSpring, Inc.$13.7M11
TVRDTvardi Therapeutics, Inc.$13.2M30

Take a look at ESLA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Estrella Immunopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about ESLA

How does Ticker Nerd's model rank ESLA?

As at 21 Nov 2026, Estrella Immunopharma, Inc. ranks 26 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (83 of 100).

What is the ESLA stock forecast for 2030?

No analyst covering Estrella Immunopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ESLA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $12 over the next 12 months.

How has ESLA stock performed over the past year?

Estrella Immunopharma, Inc. returned -79.5% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Estrella Immunopharma, Inc. do?

Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing T-cell therapies for blood cancers, solid tumors, and certain autoimmune diseases. The company is centered on CD19- and CD22-targeted ARTEMIS T-cell programs designed to harness the immune system’s ability to recognize and attack diseased cells.

Company

About Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing T-cell therapies for blood cancers, solid tumors, and certain autoimmune diseases. The company is centered on CD19- and CD22-targeted ARTEMIS T-cell programs designed to harness the immune system’s ability to recognize and attack diseased cells. Its current pipeline includes EB103 and EB104 for B-cell malignancies, along with EB201, which is being explored for systemic lupus erythematosus. Estrella Immunopharma operates in the advanced immunotherapy and cell therapy segment of the biopharmaceutical market, where it aims to address treatment challenges through engineered immune-based approaches. Headquartered in Emeryville, California, Estrella Immunopharma is positioned as a research-driven company developing next-generation therapies for oncology and autoimmune disorders.

CEO Ms. Cynthia Pussinen · United States · https://www.estrellabio.com